A recent study published in Frontiers in Endocrinology suggests that a commonly measured blood enzyme, alkaline phosphatase (ALP), could help identify individuals at risk of osteoporosis. Researchers found that elevated ALP levels were consistently linked to higher osteoporosis risk, particularly among younger, metabolically healthy women. The study also identified a potential threshold for recommending further bone health evaluations.
Osteoporosis: A Growing Health Concern
Osteoporosis is a condition marked by reduced bone mass and structural deterioration, which significantly increases fracture risk and impacts overall quality of life. With global life expectancy rising, osteoporosis prevalence is also increasing, especially among individuals over 75. This trend has amplified the need for accessible, reliable biomarkers that can detect bone loss early and prevent fractures.
ALP and Its Role in Bone Health
Alkaline phosphatase (ALP) is an enzyme produced mainly by bone-forming osteoblasts and the liver. In bone, ALP supports mineralization by breaking down pyrophosphate. Approximately half of total blood ALP originates from bone, and bone-specific ALP closely tracks with overall ALP levels in both healthy and osteoporotic populations.
Because total ALP is inexpensive and widely measured during routine health checks, researchers have explored its potential as a surrogate marker for bone health. Past studies have produced mixed results, with some reporting negative correlations between ALP and bone mineral density, while others found no clear association. Factors such as small sample sizes, population heterogeneity, and liver or metabolic disorders complicate interpretation.
Study Design and Population
To clarify ALP’s predictive value, researchers analyzed cross-sectional health examination data from a large teaching hospital in Chongqing, China, covering 2019–2024. The study included adults aged 20 and above who underwent ALP testing and dual-energy X-ray absorptiometry (DXA) scans of the hip and spine. The researchers excluded records with incomplete data and considered only the most recent test when duplicates existed.
Osteoporosis was diagnosed using WHO criteria based on DXA T-scores, with modifications applied for younger adults. Standardized clinical procedures collected anthropometric measures, blood pressure, liver ultrasounds, and biochemical markers including glucose, lipids, uric acid, and liver enzymes. Metabolic abnormalities were defined according to established medical guidelines.
Researchers performed descriptive analyses, t-tests, chi-square tests, and five logistic regression models progressively adjusting for age, sex, body composition, metabolic markers, and liver function. The study shows that higher total serum ALP consistently increases the likelihood of osteoporosis, even within normal ranges and after adjusting for multiple confounders.
Key Findings: Participant Characteristics
Among 12,835 participants, 9.5% were diagnosed with osteoporosis. Nearly all participants (99%) had ALP levels within the clinical reference range, yet those with osteoporosis had significantly higher ALP.
Older age, female sex, lower body weight, and higher waist–hip ratios were associated with osteoporosis. Additionally, individuals at higher risk had elevated systolic blood pressure, fasting glucose, total cholesterol, and HDL levels, while uric acid and liver enzymes were lower. No significant differences appeared in diastolic blood pressure, triglycerides, or LDL levels.
ALP and Osteoporosis: Strong Associations
Logistic regression showed that each 1 IU/L increase in ALP was linked to higher odds of osteoporosis. Although individual effect sizes were modest, the cumulative impact across the ALP range was significant. Associations remained robust across all adjusted models. Spline analysis revealed a mostly linear relationship, flattening at ALP levels above 100 IU/L. ROC analysis suggested poor-to-modest discrimination, identifying 72 IU/L as the optimal threshold for recommending further bone health assessments.
Subgroup Insights: Metabolic Health Matters
Subgroup analyses highlighted stronger associations—though not higher absolute risk—among women, younger adults, and individuals with normal liver enzymes and healthier metabolic profiles. Conversely, the ALP–osteoporosis link weakened or disappeared in participants with liver abnormalities or metabolic disturbances, suggesting that non-bone sources of ALP can obscure the relationship with bone health.
Interpretation and Clinical Implications
The study shows that higher total serum ALP consistently increases the likelihood of osteoporosis, even within normal ranges and after adjusting for multiple confounders.
The relationship appears strongest in younger women and metabolically healthy individuals because ALP more accurately reflects bone-derived enzyme levels when liver function is normal. Elevated ALP may indicate compensatory increases in bone turnover due to declining bone density rather than directly causing bone loss.
Strengths of the study include its large sample size, standardized clinical data, and detailed subgroup analyses. Limitations include its cross-sectional design, single-center population, and lack of information on physical activity, thyroid function, diet, and medication use.
As reported by new-medical.net, overall, an ALP threshold around 72 IU/L may serve as a practical indicator for initiating further bone health assessments. However, longitudinal studies are necessary to confirm its predictive and causal value.